Chapters

Transcript

Video

In light of the significant unmet need for AD treatment in children between the ages of 2 and 12, and even younger what do the most recent clinical trials show about the safety and efficacy of dupilumab in these young age groups?

In light of the significant unmet need for AD treatment in children between the ages of 2 and 12, and even younger what do the most recent clinical trials show about the safety and efficacy of dupilumab in these young age groups?


Created by

CMEducation Resources iQ&A Case-By-Case Atopic Dermatitis Medical Intelligence Zone

Presenter

Peter Lio, MD

Peter Lio, MD

Clinical Assistant Professor of Dermatology and Pediatrics
Feinberg School of Medicine
Northwestern University
Chicago, Illinois